Strs Ohio Has $8.86 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Strs Ohio cut its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 4.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 89,105 shares of the company’s stock after selling 3,689 shares during the quarter. Strs Ohio’s holdings in Moderna were worth $8,861,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cim Investment Management Inc. increased its holdings in shares of Moderna by 4.2% in the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock valued at $329,000 after purchasing an additional 86 shares during the last quarter. Cetera Advisor Networks LLC lifted its holdings in shares of Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after buying an additional 87 shares in the last quarter. Ancora Advisors LLC boosted its position in shares of Moderna by 41.2% in the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after acquiring an additional 96 shares during the period. Sunbelt Securities Inc. grew its stake in shares of Moderna by 7.5% in the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock valued at $211,000 after acquiring an additional 100 shares in the last quarter. Finally, Allworth Financial LP increased its holdings in shares of Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the period. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 647 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James M. Mock sold 647 shares of Moderna stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Insiders have sold a total of 94,954 shares of company stock worth $9,983,276 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Moderna Price Performance

Moderna stock opened at $103.44 on Thursday. The stock has a 50-day moving average price of $100.10 and a two-hundred day moving average price of $93.52. Moderna, Inc. has a 12 month low of $62.55 and a 12 month high of $144.93. The company has a market capitalization of $39.61 billion, a PE ratio of -8.34 and a beta of 1.62. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.61 earnings per share. Analysts expect that Moderna, Inc. will post -7.51 EPS for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Canaccord Genuity Group upped their price objective on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research report on Friday, February 23rd. HSBC reiterated a “reduce” rating and set a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Finally, Oppenheimer upgraded shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research report on Tuesday, January 2nd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and an average price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.